FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of June 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosures:
1. Annual Information Update
2. Holding(s) in Company
3. Holding(s) in Company
4. Holding(s) in Company
5. Result of AGM
6. Holding(s) in Company
Enclosure No. 1
Acambis Annual Information Update for the last 12 months
Acambis plc (the Company) announces that, in accordance with the requirements of
Prospectus Rule 5.2 issued by the Financial Services Authority, and following
publication of the Annual Report on 24 May 2006, the following information has
been published or made available to the public during the 12 months ended 31 May
2006, in compliance with laws and rules dealing with the regulation of
securities, issuers of securities and securities markets.
For the purpose of this update, only references to the information are provided.
Full copies of each item can be found at the locations specified below. The
information referred to in this Annual Information Update was correct at the
time it was published but may now be out-of-date.
1. Announcements made via a Regulatory Information Service
All documents listed below were published via a Regulatory Information Service
on the dates indicated.
Date of publication: Title
30 May 2006: Schedule 10 Notification of Major Interests in Shares
19 May 2006: Acambis announces forthcoming retirement of Chief Scientific
Officer
19 May 2006: Acambis and Baxter file oppositions to European MVA patent
11 May 2006: Schedule 10 Notification of Major Interests in Shares
09 May 2006: Results for the first quarter ended 31 March 2006
08 May 2006: Schedule 10 Notification of Major Interests in Shares
08 May 2006: Schedule 10 Notification of Major Interests in Shares
05 May 2006: Schedule 10 Notification of Major Interests in Shares
04 May 2006: Schedule 10 Notification of Major Interests in Shares
28 April 2006: Notice of Results
20 April 2006: Schedule 10 Notification of Major Interests in Shares
19 April 2006: Acambis completes enrolment of Phase 3 JE vaccine trials ahead of
schedule
18 April 2006: Acambis completes submission of US licence application for
ACAM2000 smallpox vaccine
12 April 2006: Board Change
04 April 2006: Schedule 10 Notification of Major Interests in Shares
28 March 2006: Directors' interest in shares
27 March 2006: Increase in Directors' shareholding
09 March 2006: Preliminary results - Acambis drives pipeline forward during year
of investment
28 February 2006: Acambis to announce preliminary results for 2005 on 9 March
2006
15 February 2006: Acambis announces results from Phase 1 trial to C. difficile
vaccine
07 February 2006: Acambis appoints Peter Fellner as Non-executive Director
18 January 2006: Acambis submits US licence application for ACAM2000 smallpox
vaccine
18 January 2006: Schedule 10 Notification of Major Interests in Shares
09 January 2006: Blocklisting six monthly return
20 December 2005: Acambis becomes first company to enter Phase II testing of
vaccine against West Nile virus
02 December 2005: Acambis completes delivery of 500,000 doses of MVA3000
smallpox vaccine to US Government
28 November 2005: Acambis starts Phase I trial of C. difficile vaccine in
elderly subjects
15 November 2005: Acambis achieves major milestone in JE vaccine development
with start of Phase III pivotal clinical testing
15 November 2005: Acambis announces third quarter results and hosts R&D Day
08 November 2005: Acambis joins forces with Bharat Biotech to address unmet need
for JE vaccine in India
01 November 2005: Acambis to announce third quarter results and host R&D Day on
15 November 2005
20 October 2005: Schedule 10 Notification of Major Interests in Shares - Replace
20 October 2005: Schedule 10 Notification of Major Interests in Shares
14 October 2005: Directors' interest in shares
04 October 2005: Acambis submits proposal to supply a stockpile of MVA smallpox
vaccine to the US Government
27 September 2005: Schedule 10 Notification of Major Interests in Shares
19 September 2005: Acambis helps Cangene win C-VIG supply contract from UK
Department of Health
14 September 2005: Directors' interest in shares
13 September 2005: Schedule 10 Notification of Major Interests in Shares
06 September 2005: Q2 results - Acambis invests in progressing and expanding R&D
pipeline
01 September 2005: Schedule 10 Notification of Major Interests in Shares
26 August 2005: Schedule 10 Notification of Major Interests in Shares
26 August 2005: Schedule 10 Notification of Major Interests in Shares
23 August 2005: Acambis announces results of ChimeriVax-JE bridging study; on
track to commence Phase III trials in 2005
22 August 2005: Statement re MVA
16 August 2005: Acambis welcomes start of US Government process for purchasing a
stockpile of MVA smallpox vaccine
08 August 2005: Schedule 10 Notification of Major Interests in Shares
04 August 2005: Acambis to announce second quarter results on 6 September 2005
04 August 2005: Acambis enters flu vaccine arena with launch of flu vaccine
development programme
26 July 2005: Acambis commences Phase I trial of C. difficile vaccine
14 July 2005: Acambis announces start of MVA3000 Phase II trial
13 July 2005: Schedule 10 Notification of Major Interests in Shares
08 July 2005: Blocklisting six monthly return
08 July 2005: Comment re press speculation
13 June 2005: Schedule 10 Notification of Major Interests in Shares
Copies of the documents published via RNS may be obtained from the Regulatory
News Service provided by the London Stock Exchange (http://
www.londonstockexchange.com/en-gb/pricesnews/marketnews/) and any related
documents are available at the UK Listing Authority's Document Viewing Facility,
Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14
5HS, UK.
2. Documents filed at Companies House
The Company has submitted filings to Companies House in relation to the
appointment and resignation of directors, the allotment of shares, the adoption
of new articles of association and prints of special resolutions passed at the
Company's Annual General Meeting on 10 May 2005.
Electronic copies of these documents can be purchased from Companies House via
its website at www.companies-house.gov.uk, and hard copies can be obtained from
Companies House, Crown Way, Cardiff CF14 3UZ, UK.
3. Documents filed with the Securities and Exchange Commission
The Company has submitted filings to the Securities and Exchange Commission by
virtue of having American Depositary Shares listed on the NASDAQ Stock Exchange.
Full details can be viewed at http://www.sec.gov/edgar/searchedgar/
companysearch.html. From this page, enter the Company's mnemonic, ACAM.
The Company's Annual Report for the year ended 31 December 2005 (published on 25
May 2006) can be found on the Company's website, as can the quarterly results
announcements, published on 6 September 2005 (second quarter results), 15
November 2005 (third quarter results), 9 March 2006 (preliminary full-year
results) and 9 May 2006 (first quarter results). The Company's website is
www.acambis.com.
Copies of all documents referred to above are also available for inspection at
the Company's registered office (Peterhouse Technology Park, 100 Fulbourn Road,
Cambridge CB1 9PT, UK) during normal business hours or by request from the
Company Secretary.
Further information regarding the Company and its activities is available at
www.acambis.com.
Enquiries:
Elizabeth Brown, Company Secretary
Lyndsay Wright, VP, Communications and Investor Relations
Tel: +44 (0) 1223 275 300
Enclosure No. 2
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
AMVESCAP PLC
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
Vidacos Nominees Limited 24,460,730 shares
HSBC Nominees Limited 148,400 shares
Chase Nominees Limited 499,980 shares
Bank of New York 122,899 shares
Bank of New York (Singapore) 38,910 shares
JP Morgan Chase 113,429 shares
Northern Trust Nominees Limited 640,672 shares
Bank of Ireland (Dublin) Nominees Limited 354,380 shares
Mellon Bank (Pittsburg) Nominees Limited 365,000 shares
Japan Trustee Services Bank 4,034 shares
State Street London 4,920,000 shares
Trust and Custody Services JP 6,631 shares
5. Number of shares / amount of stock acquired
590,000 shares
6. Percentage of issued class
0.55%
7. Number of shares / amount of stock disposed
N/a
8. Percentage of issued class
N/a
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
13 June 2006
11. Date company informed
14 June 2006
12. Total holding following this notification
31,675,065 shares
13. Total percentage holding of issued class following this notification
29.50%
14. Any additional information
The above holding includes the notifiable interest of INVESCO Perpetual UK ICVC
Series (UKICVC), holding 21,472,981 shares (20.00%)
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
15 June 2006
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure No. 3
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Phylon Fund Limited
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
The legal entity holding these shares is:
Goldman Sachs Security Nominees Limited
5. Number of shares / amount of stock acquired
250,000 shares
6. Percentage of issued class
0.23%
7. Number of shares / amount of stock disposed
N/A
8. Percentage of issued class
N/A
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
15 June 2006
11. Date company informed
16 June 2006
12. Total holding following this notification
4,400,000 shares
13. Total percentage holding of issued class following this notification
4.10%
14. Any additional information
N/A
15. Name of contact and telephone number for queries
Elizabeth Brown tel: 01223 275300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown, Company Secretary
Date of notification
19 June 2006
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure No. 4
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Legal & General Investment Management Limited
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
HSBC Global Custody Nominee (UK) Ltd - various accounts
5. Number of shares / amount of stock acquired
Not disclosed
6. Percentage of issued class
Not disclosed
7. Number of shares / amount of stock disposed
N/A
8. Percentage of issued class
N/A
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
Not disclosed
11. Date company informed
16 June 2006
12. Total holding following this notification
6,497,200 shares
13. Total percentage holding of issued class following this notification
6.05%
14. Any additional information
N/a
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
19 June 2006
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure No. 5
Result of Annual General Meeting
Cambridge, UK - 23 June 2006 - At the Annual General Meeting of Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM), held today, all resolutions were passed.
Copies of the approved resolutions will be submitted to the UK Listing Authority
and will shortly be available for inspection at the UK Listing Authority's
Document Viewing Facility, which is situated at:
Financial Services Authority
25 The North Colonnade
Canary Wharf
London E14 5HS
Tel: +44 (0) 20 7676 1000
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations
Enclosure No. 6
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 27 June 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 26 June 2006, Acambis received notification that, as of the close of business
on 21 June 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street,
New York, NY 10004, USA, was interested in a total of 6,568,426 ordinary shares
of 10p each, representing a 6.12% holding of Acambis' issued share capital.
Of these 6,568,426 shares:
a) the interest in 522,095 shares arose from an interest held
by Goldman, Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman Sachs
Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by
GS&Co, acting as custodian of 1,850 American Depositary Receipts ("ADRs"); these
ADRs are, or will be, held at The Depositary Trust Company, New York;
c) the interest in 6,043,031 shares arose from a beneficial
interest held by Goldman Sachs International, a direct subsidiary of GS Inc;
these shares are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 30 June 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.